Jason Duncan

CIK: 0001741553

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)3 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NMRA

Neumora Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

NMRA
Neumora Therapeutics, Inc.
Aug 20, 2026
Award(A)
Stock Option (Right to Buy)
Direct
375K shares-
NMRA
Neumora Therapeutics, Inc.
Jan 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
750K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
400K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
500K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
400K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
500K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
500K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
400K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
400K shares-

		Type	Shares	Price		Ownership
Aug 20, 2026	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	375,000	-	-	Direct
Jan 8, 2026	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	750,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	400,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	500,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	400,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	500,000	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	500,000	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	400,000	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	400,000	-	-	Direct

1-9 of 9 transactions

About Duncan Jason

Duncan Jason (SEC CIK 0001741553) files insider reports with the SEC as Officer of Neumora Therapeutics, Inc. (NMRA).

Signal8 holds 4 ownership filings by Duncan Jason, all Form 4s, filed between Feb 18, 2025 and Aug 21, 2026. Those filings report 9 transactions, from Feb 13, 2025 to Aug 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Duncan Jason's filings is in WATERTOWN, MA.

Recent filings by Duncan Jason

Aug 20, 2026: Grant or award of NMRA derivative securities (Form 4, code A).
Jan 8, 2026: Grant or award of NMRA derivative securities (Form 4, code A).
May 28, 2025: Grants or awards of NMRA derivative securities (2 lines, Form 4, code A).
May 28, 2025: Disposition to issuer transactions of NMRA derivative securities (2 lines, Form 4, code D).
Feb 13, 2025: Grant or award of NMRA derivative securities (Form 4, code A).

Other insiders filing for Neumora Therapeutics, Inc. (NMRA)

How to read Form 4 transaction codes